Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Authors: Arlene Chan, Suzette Delaloge, Frankie A. Holmes, Beverly Moy, Hiroji Iwata, Vernon Harvey, Nicholas J. Robert, Tajana Silovski, Erhan Gökmen, Gϋnter von Minckwitz, Bent Ejlertsen, Stephen Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Marc Buyse, Ira Gore, John W. Smith, Graydon Harker, Norikazu Masuda, Katarína Petráková, Ángel Guerrero Zotano, Nicholas Iannotti, Gladys Rodriguez, Pierfrancesco Tassone, Alvin Wong, Richard Bryce, Yining Ye, Bin Yao, Miguel Martín - The Lancet 2016 cited by 565